Can intrabodies serve as neuroprotective therapies for parkinson's disease? beginning thoughts

Mansi A. Bhatt, Anne Messer, Jeffrey H. Kordower

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Misfolded proteins and subsequent protein aggregation appears to underlie a significant fraction of neurodegenerative diseases including Parkinson's disease. One of the neuropathological hallmarks of Parkinson's disease is the presence of α-syn containing intracellular inclusions known as Lewy bodies and Lewy neurites. Intrabodies are antibody fragments that have been engineered to be expressed intracellularly. They can be directed towards specific target antigens present in various subcellular locations, and have shown promise in cancer, HIV, autoimmune diseases, and Huntington's disease. More recently they have been shown to modulate abnormalities caused by aggregated α-syn in cell culture. This mini-review mainly focuses on summarizing structural and cellular effects of intrabodies shown to have affinity for different forms of α-synuclein (monomeric, oligomeric and fibrillar), as well as those exhibiting affinity for particular residues of α-synuclein (e.g., the NAC region, C terminal region).

Original languageEnglish (US)
Pages (from-to)581-591
Number of pages11
JournalJournal of Parkinson's Disease
Issue number4
StatePublished - 2013
Externally publishedYes


  • Alpha-synuclein
  • Intrabodies
  • Nanobodies
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Can intrabodies serve as neuroprotective therapies for parkinson's disease? beginning thoughts'. Together they form a unique fingerprint.

Cite this